TB-500
Grade BWidely used in veterinary medicine and reported anecdotally by athletes for muscle, tendon and ligament recovery. Human clinical data is limited to small pilot studies in dermal wound healing.
Mechanism of Action
Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.
Typical Protocol
Dose
2–5 mg
Frequency
2× per week loading (4 weeks), then 2–5 mg weekly maintenance
Duration
6–8 week loading phase, then maintenance
Timing
Any time of day; rotate injection sites
Route
Subcutaneous or intramuscular injection
Half-life
~2 hours (short systemic), with sustained tissue effects
Educational reference only — not medical advice.
Reported Benefits
- Accelerated soft-tissue and tendon recovery in preclinical models
- Improved range of motion after acute injury (case reports)
- Wound healing and reduced fibrosis
- Cardiac repair signal in animal MI models
Side Effects
- Injection site reactions
- Temporary lethargy or head rush after dosing
- Long-term human safety not characterized
Contraindications
- Active malignancy (theoretical angiogenic concern)
- Pregnancy and lactation
Known Interactions
AnticoagulantsTheoretical effect on tissue remodeling — caution.
BPC-157Frequently co-stacked; no formal interaction studies.
References
Comparison vs Alternatives
All Peptides →| Attribute | TB-500This page | BPC-157 | Semaglutide |
|---|---|---|---|
| Evidence | Grade B | Grade B | Grade A |
| Category | Regenerative | Regenerative | Metabolic |
| Best for | Soft tissue regeneration | Tissue repair, gut integrity | GLP-1 receptor agonist |
| Typical dose | 2–5 mg | 250–500 mcg | 0.25 → 2.4 mg |
| Frequency | 2× per week loading (4 weeks), then 2–5 mg weekly maintenance | 1–2× daily | Weekly |
| Route | Subcutaneous or intramuscular injection | Subcutaneous or oral (gut-localized) | Subcutaneous weekly (oral form available) |
| Legal status | WADA-prohibited at all times (S2 class). Research chemical; not approved for human therapeutic use. | Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions. | FDA-approved (Ozempic, Wegovy). Prescription required. |
| Action | Current page | View → | View → |